KalshiVerfügbarkeit prüfenKYC erforderlich2% GebührVerifizierte AuflösungsdatenOrdentlich kalibriertAktuelle implizite Wahrscheinlichkeit
Before 2028 72%Führend unter 3 Optionen
Marktqualitat
46 / 100
Niedrige Qualität24h-Volumen
451,8 €
Liquidität
2121,9 €
Niedrige LiquiditätSpread
6.0 pt
Breiter SpreadMarktdaten
Aktualisiert vor 3 Minuten
24. März 26, 14:00 UTC1. Juli 27, 03:59 UTC
Trends
Verwandte Märkte
Verwandte Fragen als Kontext, kein Vergleich gleichwertiger Kontrakte.
When will Intellia Therapeutics submit a BLA for Lonvo-z?
KalshiWill the FDA approve retatrutide?
KalshiWill the FDA approve any psychedelic substance for medical use this year?
KalshiWill FDA approve any mRNA vaccine against melanoma before 2028?
Manifold MarketsWill FDA approve any mRNA vaccine against any type of herpes simplex infection before 2028?
Manifold MarketsWill the FDA approve a psychedelic-assisted therapy for a mental disorder by 2027?
Manifold MarketsRegeln
If the FDA approves Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema for marketing before Jul 1, 2027, then the market resolves to Yes.
- If the FDA approves Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema for marketing before Oct 1, 2027, then the market resolves to Yes.
- If the FDA approves Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema for marketing before Jan 1, 2028, then the market resolves to Yes.
Offene Märkte
Health & Medicine
POLYMARKETEbola pandemic in 2026?
- No+1.1pt97%
- Yes-1.1pt3%
- Gesamtvolumen
- 650.139,4 €
- 24h-Volumen
- 29.718,1 €
POLYMARKETHantavirus pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Gesamtvolumen
- 15,6 Mio. €
- 24h-Volumen
- 20.486,4 €
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No96%
- Yes+1.9pt4%
- Gesamtvolumen
- 1,6 Mio. €
- 24h-Volumen
- 5178 €
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+6.0pt64%
- September+2.0pt41%
- June28%
- Gesamtvolumen
POLYMARKETNew pandemic in 2026?
- No93.1%
- Yes6.9%
- Gesamtvolumen
- 915.107,8 €
- 24h-Volumen
- 3244,5 €
KALSHIWhen will Intellia Therapeutics submit a BLA for Lonvo-z?
- before 2027+8.0pt84%
- before April 202781%
- before December+1.0pt69%
+3 weitere Ergebnisse
- Gesamtvolumen
- 14.247,1 €
- Measles cases in 2026?
- New pandemic before 2028?
- Ebola pandemic in 2026?
- Will the FDA approve any psychedelic substance for medical use this year?
- Measles cases in U.S. in 2026?
- When will the FDA reclassify BPC-157 to Category 1?
- FDA approves Retatrutide this year?
- Which countries will report an Ebola case in 2026?
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- Which countries will have an Ebola case in 2026?
- How many human screwworm cases will be reported in the United States in 2026?
Häufige Fragen
- Wie stehen die aktuellen Quoten für When will the FDA approve Intellia Therapeutics' lonvo-z??
- Kalshi bewertet Before 2028 mit 72% (Stand: 8. September 2026).
- Wann wird When will the FDA approve Intellia Therapeutics' lonvo-z? entschieden?
- When will the FDA approve Intellia Therapeutics' lonvo-z? soll am 1. Juli 2027 entschieden werden.
- Wie wird When will the FDA approve Intellia Therapeutics' lonvo-z? abgerechnet?
- Kalshi rechnet diesen Markt wie folgt ab: If the FDA approves Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema for marketing before Jul 1, 2027, then the market resolves to Yes.